Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Results from the 2008 Global Venture Capital Survey
June 2, 2008
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Presenters
• Mark Jensen, Deloitte & Touche LLP– Partner and National Director, Venture Capital Services
• Dixon Doll, DCM– Co-Founder and General Partner
• Jean-François Formela, Atlas Venture– Life Sciences Partner
• Emily Mendell, National Venture Capital Association– Vice President, Strategic Affairs
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Agenda
• Overview• Survey results• VC commentary• Questions and answers
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Responses and demographics
• 398 responses from around the globe– 41% from U.S.– 20% from Asia Pacific– 19% from Europe (excluding UK)– 10% from Americas (excluding U.S.)– 4% from Israel– 6% from UK
• Responses from large, mid-sized and small firms• 57% of U.S. and 58% of non-U.S. VCs are currently
investing outside of their home country
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Percentage of venture capitalists currently investing outside their home country
46%
83%
29%
61%
20%
56%57% 55%
41%
83%
40%48%
0%10%20%30%40%50%60%70%80%90%
100%
U.S. UK The Americas(excl. U.S.)
Europe (excl. UK) Israel APAC
20072008
Investing abroad
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Telecommunications
Telecommunications - primary and secondary countries with the best technology (all respondents)
9%
7%
12%
15%
14%
3%
6%
4%
12%
57%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
S. Korea
Finland
Israel
Japan
U.S.
PrimarySecondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Telecommunications (continued)
Telecommunications - countries with the best technology (total responses)
8%
6%
6%
16%
37%
5%
35%
6%
7%
8%
13%
36%
7%
9%
12%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
S. Korea
Finland
Israel
Japan
U.S. Globalnon-U.S.U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Semiconductors including electronics
Semiconductors including electronics - primary and secondary countries with the best technology (all respondents)
11%
13%
19%
21%
11%
3%
3%
7%
10%
70%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
S. Korea
China
Japan
Taiwan
U.S.
Primary
Secondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Semiconductors including electronics (continued)
Semiconductors including electronics - countries with the best technology (total responses)
5%
9%
14%
19%
43%
8%
7%
12%
13%
39%
7%
8%
13%
15%
41%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
S. Korea
China
Japan
Taiwan
U.S.
Global
non-U.S.
U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Software
Software - primary and secondary countries with the best technology (all respondents)
9%
11%
13%
35%
4%
0%
1%
0%
6%
87%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Germany
Israel
UK
India
U.S.
Primary
Secondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Software (continued)
Software - countries with the best technology(total responses)
5%
5%
5%
23%
50%
4%
6%
7%
18%
45%
4%
6%
6%
20%
47%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Germany
Israel
UK
India
U.S.Global
non-U.S.
U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Biopharmaceuticals
Biopharmaceuticals - primary and secondary countries with the best technology (all respondents)
9%
12%
16%
28%
9%
1%
3%
2%
3%
85%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
France
Germany
Switzerland
UK
U.S.
Primary
Secondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Biopharmaceuticals (continued)
Biopharmaceuticals - countries with the best technology(total responses)
4%
6%
9%
14%
53%
5%
8%
8%
15%
48%
5%
7%
8%
14%
50%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
France
Germany
Switzerland
UK
U.S.Global
non-U.S.
U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Medical devices and equipment
Medical devices and equipment - primary and secondary countries with the best technology (all respondents)
9%
12%
18%
33%
9%
1%
2%
2%
6%
85%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Japan
Israel
UK
Germany
U.S.
Primary
Secondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Medical devices and equipment (continued)
Medical devices and equipment - countries with the best technology (total responses)
5%
9%
11%
14%
54%
4%
4%
8%
21%
47%
4%
6%
10%
19%
50%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Japan
Israel
UK
Germany
U.S. Global
non-U.S.
U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Alternative / clean energy
Alternative / clean energy - primary and secondary countries with the best technology (all respondents)
6%
8%
8%
22%
23%
2%
1%
4%
21%
56%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Canada
UK
Japan
Germany
U.S.
Primary
Secondary
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Alternative / clean energy (continued)
Alternative / clean energy - countries with the best technology(total responses)
4%
4%
8%
17%
46%
4%
5%
5%
24%
35%
6%
8%
8%
22%
23%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Canada
UK
Japan
Germany
U.S. Global
non-U.S.
U.S.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Venture capital commentary –Dixon Doll
COFOUNDER AND GENERAL PARTNER, DCM
For more than 35 years, Dixon has influenced and guided entrepreneurs, investors and executives in the computer and communications industries. In recognition of his accomplishments in venture capital, Dixon was named by Forbes Magazine as one of the top 100 venture investors on its Midas List for the past four years, as well as one of the top 100 personalities involved in creating the information highway by Upside Magazine. In April, 2008, he was elected as chairman of the National Venture capitalAssociation.
Since the early 1980s, Dixon has been a telecom and Internet venture capital pioneer. In 1996 he launched DCM, an early stage technology venture capital firm which currently has more than $1.5 Billion under management, headquartered in Menlo Park, California. DCM has backed such well known entrepreneurial companies as About.com, @Motion,Clearwire, 51job, Foundry Networks, Internap, Ipivot, Neutral Tandem, PGP Corp., Recourse Technologies, Semiconductor Manufacturing International Corp, and Sling Media. DCM has become widely recognized as one of the top Silicon Valley venture firms actively investing in China and Japan. In the mid-1980’s, Dixon cofounded the venture capital industry’s first fund focused exclusively on telecommunications opportunities. Those funds he organized launched such noteworthy companies as Alantec, Bridge Communication, Centillion Networks, Network Equipment Technologies, Optilink, Picturetel, Polycom, and UUNet.
He received his B.S.E.E. degree (cum laude) from Kansas State University as well as M.S. and Ph.D. degrees in Electrical Engineering from the University of Michigan, where he was a National Science Foundation scholar.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Venture capital commentary –Jean-Francois Formela
PARTNER, ATLAS VENTURE
Jean-François Formela is a Partner in the life sciences group, and joined Atlas Venture in 1993 to help build the US life sciences franchise.
Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the healtheconomics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University Hospital in Paris.
Since joining Atlas Venture, Jean-François has been involved in the formation of companies such as Archemix, ArQule (NASDAQ: ARQL), Aureon Laboratories, Cellzome, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP). He was also an investor in Ciphergen Biosystems (NASDAQ: CIPH) and Nuvelo (NASDAQ: NUVO). Jean-François currently serves on the boards of Atlas portfolio companies Achillion Pharmaceuticals (NASDAQ: ACHN), ARCA biopharma, Proprius Pharmaceuticals, Resolvyx Pharmaceuticals and SGX Pharmaceuticals (NASDAQ: SGXP).
Jean-François received his MD from Paris University School of Medicine, and his MBA from Columbia University.
Questions & Answers
Copyright © 2008 Deloitte Development LLC. All rights reserved.
Methodology• The Deloitte and NVCA 2008 Global Venture Capital Survey was conducted jointly by
Deloitte & Touche LLP and the National Venture Capital Association. It was administered to venture capitalists in the Americas, Asia Pacific (APAC), Europe, the Middle East. Deloitte received 398 responses from general partners with assets under management ranging from less than $100 million to greater than $1 billion. The survey was conducted during March 2008. Of the total number of respondents, 398, 41% were based in the U.S., 10% in The Americas (excluding U.S.), 19% in Europe (excluding UK), 4% in Israel, 6% in the UK and 20% in APAC.
Copyright © 2008 Deloitte Development LLC. All rights reserved.
This presentation contains general information only and is based on the experiences and research of Deloitte practitioners. Deloitte is not, by means of this presentation, rendering business, financial, investment, or other professional advice or services. This presentation is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte, its affiliates, and related entities shall not be responsible for any loss sustained by any person who relies on this presentation.